Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2006

View Archived Issues

Janssen claims new anxiolytics in patent literature

Anthrax vaccine rPA-102 well tolerated, induces antibody responses in humans

Bicifadine well tolerated, improves low back pain in clinical studies

Trial data reveal efficacy and safety of extended-release paliperidone ER in schizophrenia

Recent patents impart new therapeutic agents for cancer

AEE-788 effective in an animal model of thyroid cancer

Phase II data on combretastatin A-4 phosphate in ATC warrants future trials

MerLion completes merger with Combinature Biopharm and Athelas

Medarex and GenPat77 to develop antibody products for autoimmune diseases

Auriga and Degussa to develop corticosteroid formulation for GI diseases

NIH to study prime-boost approach in HIV

Citalopram prevents depression in patients undergoing treatment for head and neck cancer

Once-daily dosing of oral methylnaltrexone studied in phase II trial

GammaCan and Life Therapeutics sign term sheet for VitiGam collaboration

Diamyd shows efficacy in phase II type 1 diabetes study

Innovive licenses patent rights to novel doxorubicin prodrug

Further positive phase II findings for Trinam

Phase III results for telavancin in cSSSI

Fresenius Kabi and Sandoz to develop HESylated biopharmaceutical

Acthar Gel sNDA in infantile spasms accepted for review

CE Mark for Repel-CV to reduce adhesions following cardiac surgery

Keppra receives FDA approval for juvenile myoclonic epilepsy

Garenoxacin submission withdrawn in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.